Trial ID or NCT#

NCT01803867

Status

NOT RECRUITING

Purpose

This is a Phase I, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of single intravenous (IV) administrations of rHIgM22 in patients with all clinical presentations of MS.

Official Title

A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)

Eligibility Criteria

Ages Eligible for Study: 18 Years to 70 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Jeffrey Dunn, MD
Multiple sclerosis specialist
Clinical Professor, Neurology & Neurological Sciences

Contact us to find out if this trial is right for you.

CONTACT

Ricardo Valenzuela
(650) 725-7545